Condé Nast is forecasting a fourth-quarter advertising revenue shortfall of more than $35 million, according to Adweek, citing internal documents and sources familiar with the business. The publisher, known for titles like Vogue and The New Yorker, is also dealing with a wave of executive departures, including CEO Roger Lynch and several leaders in its revenue organisation.

Sources told Adweek that Condé Nast’s revenue strategy has been undermined by turnover in its sales leadership and by targets set to accommodate senior editorial figures. The company’s flagship event, Vogue World, is expected to generate less than $20 million this year, well below last year’s nearly $30 million, though a company spokesperson said the Milan edition brought in $26 million. Staff reductions have already taken place in recent years to offset missed budgets.

Industry observers say the lack of a clear commercial strategy is compounding Condé Nast’s challenges. Some insiders described a demoralised leadership team and unclear direction, raising questions about the company’s ability to stabilise its revenue base. For senior brand and marketing leaders, the situation at Condé Nast offers a warning on the risks of leadership churn and over-optimistic targets.

Thrive Holdings, the holding company spun out from Thrive Capital and backed by OpenAI, has acquired home security firm ADT for $10 per share, or about $7.6 billion in equity, with a total enterprise value of $15.3 billion. The deal aims to make ADT the core of Thrive’s smart home security business, according to the companies.

OpenAI, as a partner and investor, will provide AI models, technology, and engineers to Thrive’s portfolio, which now includes more than 75 companies. While no new products were announced, Thrive and ADT plan to invest in and release new AI-powered security offerings.

The move comes as competition in AI-driven home security intensifies. Apple recently launched smart home security products with LG and Schneider Electric, and Amazon has updated its AI-powered cameras. ADT already works with Apple and Google, and these partnerships are expected to continue.

For insurers and tech firms, the integration of AI into physical security could affect risk models, claims, and product offerings. The sector may see further consolidation or new partnerships as AI capabilities expand.

STAT reports that Vertex’s kidney disease drug is being closely examined for infection risk as the FDA prepares to make an approval decision on 30 November. The scrutiny reflects regulatory attention to safety concerns in new therapies, especially for high-risk patient groups.

For pharma executives, this signals the importance of addressing safety data in regulatory submissions and market planning. The FDA’s approach may influence how similar drugs are evaluated and could shape future approval timelines and requirements.

A proposed Treasury rule has caused disagreement in the biopharma industry, according to STAT. The dispute centres on an exemption for a common type of transaction involving China, which some firms argue could affect their business models and partnerships.

This matters for pharma and biotech executives, as regulatory changes may alter the risk profile of cross-border deals and impact drug development timelines. Firms should review their exposure to affected deal types and prepare for possible adjustments if the rule is finalised.

A Trump administration rule will force pharmacy benefit managers to disclose fees and compensation details currently kept private, according to STAT. The move targets the opaque financial arrangements that have long shaped drug pricing in the US.

This matters for health insurers and pharmaceutical firms, as greater transparency could change how contracts are structured and how much is paid for medicines. It may also prompt further regulatory attention to pricing practices in the sector.

A White House-backed plan to relax FDA oversight on certain peptide drugs was opposed by most FDA scientific staff, who had little input in drafting the policy, according to Fast Company. The proposal, driven by Health Secretary Robert F. Kennedy Jr., would allow specialty pharmacies to sell some injectable peptides without the usual FDA review. The policy recently underwent regulatory review at the White House, which is typically the last step before publication.

This internal resistance signals regulatory uncertainty for pharma and healthcare leaders, as FDA staff warned the move could undermine the agency’s mission to keep unproven drugs off the market. Senior executives should monitor how these divisions affect enforcement and compliance expectations.

Eli Lilly said its investigational drug retatrutide was more effective at lowering blood sugar and reducing weight than Novo Nordisk’s Ozempic in a large diabetes study, according to STAT. The announcement positions Lilly as a strong competitor in the diabetes treatment market.

For pharma executives, this signals a shift in the competitive field for diabetes therapies. The result could influence future regulatory reviews, payer decisions and market share in a major therapeutic area.

Capital One, one of the largest US banks, has used artificial intelligence to reduce quality errors in audit risk and compliance by 85%, according to MIT Sloan Management Review. The bank’s intelligent assistant, built using open-weight models and advanced analytics, has also saved 5,000 audit hours across 30 auditors in a few months, with one task cut from five hours to three minutes. AI is also used for fraud reduction, software development, and customer service, including generative AI to help agents answer customer queries more quickly and accurately. Several hundred agents now use AI-powered call summarisation, which has improved productivity and customer experience.

Capital One’s leaders say the bank’s approach to AI is focused on enterprise-wide capabilities, not just individual productivity. Training is prioritised to ensure staff can use new tools effectively. The bank’s chief enterprise AI officer, Prem Natarajan, argues that transformation with AI cannot be measured by short-term ROI, but by long-term customer satisfaction and operational improvement.

For regulated-industry leaders, the Capital One example shows the scale of operational gains possible from AI in core risk and compliance functions. The bank’s focus on training and enterprise adoption may offer a model for other financial institutions and insurers seeking to improve quality and efficiency at scale.

STAT reports that nonprofit Bon Secours Mercy Health has agreed to acquire a surgery centre chain in a $5.7 billion deal. The transaction would make the Catholic health system one of the largest operators of outpatient surgery centres in the US.

This scale could affect how hospitals, insurers, and independent practices compete for outpatient procedures. Senior executives should consider the impact on referral flows, pricing power, and future consolidation in the sector. The deal may also prompt regulatory interest in market concentration.

STAT reports that Artiva is shutting down its autoimmune cell therapy trial after two patients died. The news comes as drugmakers have shown interest in using cancer therapy strategies for autoimmune conditions, but these recent deaths have raised new concerns about safety and risk.

For senior executives in biotech and pharma, this development signals increased scrutiny on adapting cancer treatments for other diseases. Companies may need to reassess trial protocols and risk management processes. The outcome may affect investor confidence and regulatory expectations in the sector.